top of page
Search

New hope in the treatment of advanced cancers

The AMDC Solution

This research introduces an ingenious solution to the hurdles associated with post-translational modification of proteins, complex manufacturing process and variability in the internalization in cancer cells. The key lies in a method that fuses a monomeric anti-HER2 VHH to “Cupid”, resulting in "anti-HER2 VHH-Cupid." This tetrameric protein can be conveniently purified based on molecular weight, which streamlines production in manufacturing.

A Potent Complex: Duo-HER2 (STI-002)

Anti-HER2 VHH-Cupid non-covalently binds with "Psyche" linked to a potent DNA-alkylating agent, duocarmycin. This complex effectively targets and destroys HER2-expressing human cancer cells in vitro and in vivo, ushering in a new era of cancer treatment.

Promising Cancer Therapy Platform

Savid’s AMDC technology promises to revolutionize cancer therapy by combining targeting precision with potent payloads and streamlined manufacturing. Researchers anticipate significant improvements in patient outcomes and a reduction in traditional treatment side effects.

For media inquiries or more information, please contact:

Michael Chansler, Vice President Business Development, Savid Therapeutics, Inc. mchansler@savidtherapeutics.com

22 views0 comments

Comments


bottom of page